| abstract |
The invention relates to compounds of the formula I:n nwherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is -O-, -NH- or -S-; n is 0-5; m is 0-3; R 1 and R 2 are defined herein including groups: n(i) Q 1 X 1 wherein Q 1 and X 1 are as defined herein; n(ii) Q15W 3 wherein Q 15 and W 3 are as defined herein, n(iii) Q 21 W 4 C 1-5 alkylX 1 - wherein Q 21 , W 4 and X 1 are as defined herein, n(iv) Q 28 C 1-5 alkylX 1 -, Q 28 C 2-5 alkenylX 1- or Q 28 C 2-5 alkynylX 1 - wherein Q 28 and X 1 are as defined herein and n(v) Q 29 C 1-5 alkylX 1 -, Q 29 C 2-5 alkenylX 1 - or Q 29 C 2-5 alkynylx 1 - wherein Q 29 and X 1 are as defined herein; R 2 can also be 6,7-methylenedioxy or 6,7-ethylenedioxy; n nand salts thereof; their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals; processes for the preparation of such compounds; intermediates used in such processes; processes for making such intermediates; pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula I or a pharmaceutically acceptable salt thereof. The compounds of formula I inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. |